PortalPublikationenPrognostic role of decreased E-cadherin expression in patien...

Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study

Standard

Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. / Favaretto, Ricardo L; Bahadori, Atessa; Mathieu, Romain; Haitel, Andrea; Grubmüller, Bernhard; Margulis, Vitaly; Karam, Jose A; Rouprêt, Morgan; Seitz, Christian; Karakiewicz, Pierre I; Cunha, Isabela W; Zequi, Stenio C; Wood, Christopher G; Weizer, Alon Z; Raman, Jay D; Remzi, Mesut; Rioux-Leclercq, Nathalie; Jacquet-Kammerer, Solene; Bensalah, Karim; Lotan, Yair; Bachmann, Alexander; Rink, Michael; Briganti, Alberto; Shariat, Shahrokh F.

in: WORLD J UROL, Jahrgang 35, Nr. 1, 01.2017, S. 113-120.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Favaretto, RL, Bahadori, A, Mathieu, R, Haitel, A, Grubmüller, B, Margulis, V, Karam, JA, Rouprêt, M, Seitz, C, Karakiewicz, PI, Cunha, IW, Zequi, SC, Wood, CG, Weizer, AZ, Raman, JD, Remzi, M, Rioux-Leclercq, N, Jacquet-Kammerer, S, Bensalah, K, Lotan, Y, Bachmann, A, Rink, M, Briganti, A & Shariat, SF 2017, 'Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study', WORLD J UROL, Jg. 35, Nr. 1, S. 113-120. https://doi.org/10.1007/s00345-016-1835-1

APA

Favaretto, R. L., Bahadori, A., Mathieu, R., Haitel, A., Grubmüller, B., Margulis, V., Karam, J. A., Rouprêt, M., Seitz, C., Karakiewicz, P. I., Cunha, I. W., Zequi, S. C., Wood, C. G., Weizer, A. Z., Raman, J. D., Remzi, M., Rioux-Leclercq, N., Jacquet-Kammerer, S., Bensalah, K., ... Shariat, S. F. (2017). Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. WORLD J UROL, 35(1), 113-120. https://doi.org/10.1007/s00345-016-1835-1

Vancouver

Favaretto RL, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V et al. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. WORLD J UROL. 2017 Jan;35(1):113-120. https://doi.org/10.1007/s00345-016-1835-1

Bibtex

@article{2085320d3fae4a07ac00d5aca120e9b3,
title = "Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study",
abstract = "PURPOSE: To assess the role of E-cadherin as prognostic biomarker in upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients.METHODS: Immunohistochemistry technique was used to evaluate E-cadherin expression in 678 patients with unilateral, sporadic UTUC treated with RNU. E-cadherin expression was considered decreased if 10 % or more cells had decreased expression (<90 %).RESULTS: Decreased E-cadherin expression was observed in 353 patients (52.1 %) and was associated with advanced pathological stage (P < 0.001), higher grade (P < 0.001), lymph node metastasis (P = 0.006), lymphovascular invasion (P < 0.001), concomitant carcinoma in situ (P < 0.001), multifocality (P = 0.004), tumor necrosis (P = 0.020) and sessile architecture (P < 0.001). Within a median follow-up of 30 months (interquartile range 15-57), 171 patients (25.4 %) experienced disease recurrence and 150 (21.9 %) died from UTUC. In univariable analyses, decreased E-cadherin expression was significantly associated with worse recurrence-free survival (P < 0.001) and cancer-specific survival CSS (P = 0.006); however, in multivariable analyses, it was not (P = 0.74 and 0.84, respectively). The lack of independent prognostic value of E-cadherin remained true in all subgroup analyses.CONCLUSION: In UTUC patients treated with RNU, decreased E-cadherin expression is associated with features of biologically and clinically aggressive disease and worse outcome in univariable, but not multivariable, analyses. If E-cadherin's association with factors of advanced disease is confirmed on UTUC biopsy specimens, it could be used to help in the clinical decision-making regarding kidney-sparing approaches and/or neo-adjuvant chemotherapy.",
author = "Favaretto, {Ricardo L} and Atessa Bahadori and Romain Mathieu and Andrea Haitel and Bernhard Grubm{\"u}ller and Vitaly Margulis and Karam, {Jose A} and Morgan Roupr{\^e}t and Christian Seitz and Karakiewicz, {Pierre I} and Cunha, {Isabela W} and Zequi, {Stenio C} and Wood, {Christopher G} and Weizer, {Alon Z} and Raman, {Jay D} and Mesut Remzi and Nathalie Rioux-Leclercq and Solene Jacquet-Kammerer and Karim Bensalah and Yair Lotan and Alexander Bachmann and Michael Rink and Alberto Briganti and Shariat, {Shahrokh F}",
year = "2017",
month = jan,
doi = "10.1007/s00345-016-1835-1",
language = "English",
volume = "35",
pages = "113--120",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study

AU - Favaretto, Ricardo L

AU - Bahadori, Atessa

AU - Mathieu, Romain

AU - Haitel, Andrea

AU - Grubmüller, Bernhard

AU - Margulis, Vitaly

AU - Karam, Jose A

AU - Rouprêt, Morgan

AU - Seitz, Christian

AU - Karakiewicz, Pierre I

AU - Cunha, Isabela W

AU - Zequi, Stenio C

AU - Wood, Christopher G

AU - Weizer, Alon Z

AU - Raman, Jay D

AU - Remzi, Mesut

AU - Rioux-Leclercq, Nathalie

AU - Jacquet-Kammerer, Solene

AU - Bensalah, Karim

AU - Lotan, Yair

AU - Bachmann, Alexander

AU - Rink, Michael

AU - Briganti, Alberto

AU - Shariat, Shahrokh F

PY - 2017/1

Y1 - 2017/1

N2 - PURPOSE: To assess the role of E-cadherin as prognostic biomarker in upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients.METHODS: Immunohistochemistry technique was used to evaluate E-cadherin expression in 678 patients with unilateral, sporadic UTUC treated with RNU. E-cadherin expression was considered decreased if 10 % or more cells had decreased expression (<90 %).RESULTS: Decreased E-cadherin expression was observed in 353 patients (52.1 %) and was associated with advanced pathological stage (P < 0.001), higher grade (P < 0.001), lymph node metastasis (P = 0.006), lymphovascular invasion (P < 0.001), concomitant carcinoma in situ (P < 0.001), multifocality (P = 0.004), tumor necrosis (P = 0.020) and sessile architecture (P < 0.001). Within a median follow-up of 30 months (interquartile range 15-57), 171 patients (25.4 %) experienced disease recurrence and 150 (21.9 %) died from UTUC. In univariable analyses, decreased E-cadherin expression was significantly associated with worse recurrence-free survival (P < 0.001) and cancer-specific survival CSS (P = 0.006); however, in multivariable analyses, it was not (P = 0.74 and 0.84, respectively). The lack of independent prognostic value of E-cadherin remained true in all subgroup analyses.CONCLUSION: In UTUC patients treated with RNU, decreased E-cadherin expression is associated with features of biologically and clinically aggressive disease and worse outcome in univariable, but not multivariable, analyses. If E-cadherin's association with factors of advanced disease is confirmed on UTUC biopsy specimens, it could be used to help in the clinical decision-making regarding kidney-sparing approaches and/or neo-adjuvant chemotherapy.

AB - PURPOSE: To assess the role of E-cadherin as prognostic biomarker in upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients.METHODS: Immunohistochemistry technique was used to evaluate E-cadherin expression in 678 patients with unilateral, sporadic UTUC treated with RNU. E-cadherin expression was considered decreased if 10 % or more cells had decreased expression (<90 %).RESULTS: Decreased E-cadherin expression was observed in 353 patients (52.1 %) and was associated with advanced pathological stage (P < 0.001), higher grade (P < 0.001), lymph node metastasis (P = 0.006), lymphovascular invasion (P < 0.001), concomitant carcinoma in situ (P < 0.001), multifocality (P = 0.004), tumor necrosis (P = 0.020) and sessile architecture (P < 0.001). Within a median follow-up of 30 months (interquartile range 15-57), 171 patients (25.4 %) experienced disease recurrence and 150 (21.9 %) died from UTUC. In univariable analyses, decreased E-cadherin expression was significantly associated with worse recurrence-free survival (P < 0.001) and cancer-specific survival CSS (P = 0.006); however, in multivariable analyses, it was not (P = 0.74 and 0.84, respectively). The lack of independent prognostic value of E-cadherin remained true in all subgroup analyses.CONCLUSION: In UTUC patients treated with RNU, decreased E-cadherin expression is associated with features of biologically and clinically aggressive disease and worse outcome in univariable, but not multivariable, analyses. If E-cadherin's association with factors of advanced disease is confirmed on UTUC biopsy specimens, it could be used to help in the clinical decision-making regarding kidney-sparing approaches and/or neo-adjuvant chemotherapy.

U2 - 10.1007/s00345-016-1835-1

DO - 10.1007/s00345-016-1835-1

M3 - SCORING: Journal article

C2 - 27129576

VL - 35

SP - 113

EP - 120

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 1

ER -